The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis

J Gastrointest Cancer. 2023 Dec;54(4):1376-1379. doi: 10.1007/s12029-023-00923-6. Epub 2023 Mar 7.

Authors

Fausto Petrelli¹, Michele Ghidini², Marina Macchini³, Giulia Orsi³, Umberto Peretti³, Sozzi Andrea⁴, Stefano Cascinu³, Michele Reni²

Affiliations

¹ Oncology Unit, ASST Bergamo Ovest, Treviglio, BG, Italy. faupe@libero.it.
² Oncology Unit, Fondazione Irccs Ospedale Maggiore Policlinico, Milan, Italy.
³ Department of Medical Oncology, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
⁴ Surgery Unit, ASST Bergamo Ovest, Treviglio, BG, Italy.

PMID: 36881248
DOI: 10.1007/s12029-023-00923-6

No abstract available

Keywords: Borderline resectable; Chemotherapy; Neoadjuvant; Network meta-analysis; Pancreatic cancer.

Publication types

Meta-Analysis

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Fluorouracil / therapeutic use
Humans
Leucovorin / therapeutic use
Neoadjuvant Therapy
Network Meta-Analysis
Pancreatic Neoplasms* / drug therapy
Pancreatic Neoplasms* / surgery

Substances

folfirinox
Fluorouracil
Leucovorin